APRE - Aprea Therapeutics, Inc.

1.6386
0.049   2.966%

Share volume: 70,644
Last Updated: 04-08-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.05%

PREVIOUS CLOSE
CHG
CHG%
$1.59
0.05
0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
18%
Profitability 0%
Dept financing 6%
Liquidity 50%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-3.61%
1 Month
-26.52%
3 Months
-55.17%
6 Months
-35.99%
1 Year
-72.87%
2 Year
-61.08%
Key data
Stock price
$1.64
P/E Ratio 
0.00
DAY RANGE
$1.56 - $1.80
EPS 
-$2.42
52 WEEK RANGE
$1.56 - $6.23
52 WEEK CHANGE
-$73.57
MARKET CAP 
17.881 M
YIELD 
N/A
SHARES OUTSTANDING 
5.432 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-13-2025
BETA 
1.49
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$58,278
AVERAGE 30 VOLUME 
$29,179
Company detail
CEO: Oren Gilad
Region: US
Website: atrinpharma.com
Employees: 0
IPO year: 2019
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company's lead product candidate is APR-246, a small molecule p53 reactivator, which is in late-stage clinical development for the treatment of hematologic malignancies, including myelodysplastic syndromes and acute myeloid leukemia (AML)

Recent news
loading